Oncternal Therapeutics (ONCT) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/08/24
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial ResultsGlobeNewsWire • 08/08/24
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial ResultsGlobeNewsWire • 08/01/24
Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate CancerGlobeNewsWire • 05/30/24
Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/09/24
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial ResultsGlobeNewsWire • 05/09/24
All You Need to Know About Oncternal Therapeutics (ONCT) Rating Upgrade to BuyZacks Investment Research • 05/08/24
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial ResultsGlobeNewsWire • 05/02/24
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 05/01/24
Oncternal Therapeutics (ONCT) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research • 04/25/24
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate CancerGlobeNewsWire • 04/18/24
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate CancerGlobeNewsWire • 03/15/24
Oncternal Therapeutics (ONCT) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/07/24
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 03/07/24
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 02/29/24
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/06/24
Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate CancerGlobeNewsWire • 01/08/24
Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell LymphomaGlobeNewsWire • 12/26/23
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial ResultsGlobeNewsWire • 11/09/23